Change - Announcement of Appointment::Appointment of Non-Executive Chairman of the Board of Directors
Issuer & Securities
Issuer/ Manager
SANTAK HOLDINGS LIMITED
Securities
SANTAK HOLDINGS LIMITED - SG1J68891147 - 580
Stapled Security
No
Announcement Details
Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
31-Dec-2024 12:30:10
Status
New
Announcement Sub Title
Appointment of Non-Executive Chairman of the Board of Directors
Announcement Reference
SG241231OTHR8RLH
Submitted By (Co./ Ind. Name)
Ng Huei Yee
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of Mr Chen Yeow Sin as Non-Executive Chairman of the Board of Directors, and Chairman of Audit Committee and Sustainability Committee
This announcement has been reviewed by the Company's Sponsor, Asian Corporate Advisors Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Ms Foo Quee Yin, at 160 Robinson Road #21-05, SBF Center, Singapore 068914, Telephone number: 6221 0271.
Additional Details
Date Of Appointment
01/01/2025
Name Of Person
CHEN YEOW SIN
Age
62
Country Of Principal Residence
Singapore
Date of last re-appointment (if applicable)
30/10/2024
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Mr Chen Yeow Sin ("Mr Chen") is currently the Independent Non-Executive Director, Chairman of Nominating Committee ("NC"), and a member of Audit Committee ("AC") and Remuneration Committee ("RC") of the Company.
The Board of Directors of the Company (the "Board") has, after taking into consideration the NC's recommendation, reviewed Mr Chen's performance and contributions to the Board and approved the appointment of Mr Chen as Non-Executive Chairman of the Board and Chairman of AC and Sustainability Committee ( "SC") of the Company. Mr Chen had abstained from the deliberations and decision of his appointment.
Following the aforesaid appointment, Mr Chen remains as a Chairman of NC and a member of RC.
Whether appointment is executive, and if so, the area of responsibility
The appointment is non-executive.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Non-Executive Chairman and Independent Director, Chairman of AC, NC and SC, and a member of RC.
Professional qualifications
Bachelor of Science (Honours) Degree, University of London
Fellow Singapore Chartered Accountant
Fellow Chartered Accountants in England and Wales
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
No
Conflict of interests (including any competing business)
No
Working experience and occupation(s) during the past 10 years
2012 to Present : Managing Director, One Partnership PAC
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
1. Healthway Medical Corporation Limited
2. Island Advisors Pte. Ltd.
3. Mckenzie Inter Trade Pte. Ltd.
4. Three Oceans Pte. Ltd.
5. Copro Globals Pte. Ltd.
6. Shin Nippon Biomedical Laboratories Ltd., Singapore Branch
7. Uniplas Corporation, Singapore Branch
Present
Principal Commitments including Directorships
1. One Consulting Group Pte. Ltd.
2. One Financial Advisory Services Pte. Ltd.
3. One e-Risk Services Pte. Ltd.
4. One Tax Services Pte. Ltd.
5. One Partnership PAC
6. One Outsource Services Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
Yes
If Yes, Please provide full details
Mr Chen has been an Independent Director of Healthway Medical Corporation Limited (the "HMC") since 21 July 2017. HMC and its Board of Directors had received enquiries and reminder letters dated 25 March 2021 from the Singapore Exchange Regulation Pte. Ltd. ('SGX") and communicated with the SGX, in relation to its obligations under Catalist Listing Rule 703(4)(a) read with paragraph 27(a) of the Corporate Disclosure Policy. This arose from certain inaccurate disclosures in HMC's annual report for the financial year ended 31 December 2019 ("AR 2019") pertaining to the re-election of Mr Sin Boon Ann and the appointment of Ms Poh Mui Hoon. The AR 2019 has been announced on the SGXNet on 15 April 2020 and the aforesaid disclosures were subsequently revised and corrected by way of a corrigendum to the AR 2019 announced on the SGXNet on 22 June 2020.
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
Yes
If Yes, Please provide details of prior experience
1. Healthway Medical Corporation Limited
2. Imperium Crown Limited
3. Metax Engineering Corporation Limited
4. Sitra Holdings (International) Limited
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N/A.
Related Announcements
Related Announcements